Tradestie Institutional Equity Comparison Engine

SYRE vs MRNA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MRNA Overall Edge

MRNA Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Moderna, Inc. Common Stock (MRNA) driven by superior Valuation, Momentum & Technical, Options & Structure while SYRE counters with relative strength in Growth & Margin. Fundamentally, SYRE trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus MRNA at 23.0x Forward P/E and -80.8% operating margin (+29.2% YoY). In options structure, SYRE sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro) against MRNA sits in CONSOLIDATION (30th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MRNA
SYRE N/M vs MRNA 23.0x Fwd P/E
Growth & Margin Winner SYRE
Op Margin 0.0% vs -80.8% ยท YoY +0.0% vs +29.2%
Momentum & Technical Winner MRNA
1Y +341.7% vs +765.2% ยท 52W Pos 88% vs 75%
Options & Structure Winner MRNA
UNCLASSIFIED (10th %ile IV) vs CONSOLIDATION (30th %ile IV)
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
1M Return +25.11%
1Y Return +341.74%
Forward P/E N/M
Unified AI Score
36.1 / 100 SELL
Tech 8.0 Fund 33.0 Flow 50.0 Mom 50.0
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$215.96
-3.32% 1D
Market Cap $93.6B
1M Return -0.94%
1Y Return +765.2%
Forward P/E 23.0x
Unified AI Score
46.8 / 100 HOLD
Tech 41.0 Fund 50.0 Flow 67.0 Mom 41.1

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SYRE +341.74% MRNA +765.2% Spread: +423.46 pp (MRNA Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SYRE TTM Op. Margin: 0.0% MRNA TTM Op. Margin: -80.8%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SYRE vs MRNA. Trailing 12-month operating profitability (SYRE 0.0% vs MRNA -80.8%) and valuation multiples (SYRE N/M vs MRNA 23.0x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SYRE (4) vs MRNA (6)
Institutional Metric SYRE MRNA Criterion Row Winner
Market Capitalization Scale $9.8B $93.6B Larger Scale MRNA
Trailing P/E Ratio Valuation N/M 23.0x Lower Multiple MRNA
Forward P/E Ratio Valuation N/M 23.0x Lower Multiple MRNA
Revenue Growth (YoY) Growth +0.0% +29.2% Higher Growth MRNA
Operating Margin (TTM) Profitability 0.0% -80.8% Higher Margin SYRE
Net Profit Margin Profitability 0.0% -110.5% Higher Margin SYRE
Return on Equity (ROE) Capital Efficiency -35.0% -34.5% Higher ROE MRNA
52-Week Range Position Momentum 88% ($22โ€“$111) 75% ($22โ€“$281) Stronger Trend SYRE
Beta / 30D Volatility Risk Regime 1.75ฮฒ ยท 59% Vol 2.35ฮฒ ยท 101% Vol Lower Realized Risk SYRE
Unified Institutional Score Composite Signal 36.1 / 100 (SELL) 46.8 / 100 (HOLD) Higher Composite MRNA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SYRE vs MRNA Buy Guide
SYRE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live SYRE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MRNA CONSOLIDATION
18d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 30th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SYRE nor MRNA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.